Long-Term Results of Tumor Necrosis Factor α– and Melphalan-Based Isolated Limb Perfusion in Locally Advanced Extremity Soft Tissue Sarcomas
Jan P. Deroose(Cancer Clinic), Cornelis Verhoef(Erasmus MC Cancer Institute), Jacobus W. A. Burger(Radboud University Nijmegen), Albertus N. van Geel, Alexander M.M. Eggermont(University Medical Center Utrecht), Michael A. den Bakker(Erasmus MC), Johannes H.W. de Wilt(Radboud University Nijmegen)
Cited by 100
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k